Research
Spatial transcriptomics uncovers pharmacokinetic and tumor-intrinsic determinants of resistance to trastuzumab deruxtecan in breast cancer
Cell Reports Medicine · By Changhee Park, Minki Choi, Jiwon Koh, Sungwoo Bae, Hongyoon Choi, Kwon Joong Na, Yu-Jin Kim, Sujin Ham, Juyoun Lee, Yoonjung Shin, Dae-Won Lee, Kyung-Hun Lee, Han Suk Ryu, Tae-Yong Kim & Seock-Ah Im ·
The Brief
- Park et al. performed spatial transcriptomics in patients with metastatic breast cancer treated with trastuzumab deruxtecan.
- More spatially dispersed HER2 expression correlated with improved response.
- In HER2-low tumors, resistant tumor fragments showed increased pharmacokinetic barriers.
Why it matters
The study points to spatial HER2 distribution and pharmacokinetic barriers as possible causes of resistance to a HER2-directed antibody-drug conjugate, which may inform patient selection and future drug design.
Who’s affected
- oncologists and breast cancer researchers
- clinicians treating metastatic HER2-low breast cancer
Park et al. perform spatial transcriptomics in patients with metastatic breast cancer treated with trastuzumab deruxtecan. More spatially dispersed HER2 expression correlates with improved response. In HER2-low tumors, resistant fragments show increased pharmacokinetic barriers…